The U.S. Food and Drug Administration (FDA) announced the approval of TREGZI, the first regulatory T (Treg) cell-based immunotherapy, aimed at improving survival without chronic graft-versus-host disease (GVHD) in cancer patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Summary: The FDA has approved a new treatment called TREGZI. Using donor immune cells, this therapy aims to prevent the serious complications that blood cancer patients may encounter during allogeneic hematopoietic stem cell transplantation (allo-HSCT). In particular, this treatment aims to improve survival without chronic graft-versus-host disease (GVHD). TREGZI is an immunotherapy developed with Treg cells, which help regulate the immune system, and is regarded as a significant innovation in this field.
Implications for the Turkish Clinical Trials Sector and Sponsors: This development presents a significant opportunity for the clinical trials sector in Türkiye. The approval of innovative therapies such as TREGZI opens new doors for trial sites and sponsors in Türkiye to conduct clinical trials to international standards. In particular, the increase in research on immune cells is enhancing Türkiye's potential in this field and strengthening the competitiveness of local trial sites in the global market. Moreover, the development of such treatment methods may contribute to the growth of the biotechnology and drug development sector in Türkiye.
With 29 years of experience, Omega CRO guides sponsors in adapting to current regulatory developments of this kind. Thanks to our laboratories such as HelixLab and Omega Genetics, OmegaCare, which provides home healthcare services, our biorepository services, and our technologies such as TURP and IWRS, we provide support at every stage of clinical trials. We are pleased to assist sponsors, together with our innovative solutions, in improving the quality of clinical trials in Türkiye and in achieving compliance with regulatory requirements. Contact us to achieve your goals!